Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic neurotransmission may be modulated at multiple levels, only a minority of which are currently being exploited for pharmaceutical development. Ionotropic receptors for glutamate are divided into N-methyl-D-aspartate receptor (NMDAR) and AMPA receptor subtypes. NMDAR have been implicated in the pathophysiology of schizophrenia. The glycine modulatory site of the NMDAR is currently a favored therapeutic target, with several modulatory agents currently undergoing clinical development. Of these, the full agonists glycine and D-serine have both shown to induce significant, large effect size reductions in persistent negative and cognitive symptoms when added to traditional or newer atypical antipsychotics in double-blind, placebo-controlled clinical studies. Glycine (GLYT1) and small neutral amino-acid (SNAT) transporters, which regulate glycine levels, represent additional targets for drug development, and may represent a site of action of clozapine. Brain transporters for D-serine have recently been described. Metabotropic glutamate receptors are positively (Group I) or negatively (Groups II and III) coupled to glutamatergic neurotransmission. Metabotropic modulators are currently under preclinical development for neuropsychiatric conditions, including schizophrenia, depression and anxiety disorders. Other conditions for which glutamate modulators may prove effective include stroke, epilepsy, Alzheimer disease and PTSD. Molecular Psychiatry (2004) 9, 984-997.
Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Approximately 60% of neurons in the brain, including all cortical pyramidal neurons and thalamic relay neurons, utilize glutamate as their primary neurotransmitter. 1 As a result, virtually all thalamocortical, corticocortical and corticofugal neurotransmission in the brain is mediated by glutamate. Glutamate is released from presynaptic terminals in response to neuronal depolarization, and is recycled by excitatory amino acid (EAA) transporters located on both neurons and glia. 2 Within glia, glutamate is converted to glutamine and released into extracellular fluid from which it is reabsorbed into presynaptic terminals and converted back to glutamate via action of neuronal glutaminase. Up to 2/3 of brain energy metabolism is related to reuptake and recycling of glutamate. 3 As such, functional imaging modalities, such as PET and fMRI, indexing activity primarily of brain glutamatergic systems. 4 The exchange of glutamine from glia to neurons is accomplished by coordinated actions of two transport systems, systems N and A, both of which are members of sodium-dependent neutral amino acid (SNAT) family of transporters. 5 These transport systems also transport precursors for cysteine and glycine, which are precursors to glutathione synthesis. 6 As these transporters are electrogenic, glutamate transporters may also participate in cellular signaling. 7 As with glutamate and GABA transporters, these recycling systems may constitute interesting targets for psychopharmaceutical research.
Glutamate receptor subtypes
Receptors for glutamate are divided into two broad families ( Figure 1 ). Ionotropic receptors are differentiated based upon sensitivity to the synthetic glutamate derivatives N-methyl-D-aspartate (NMDA), AMPA and kainate. Metabotropic receptors, which are G protein coupled and mediate longer-term neuromodulatory effects of glutamate, are divided into groups on the basis of effector coupling and ligand sensitivity.
NMDA receptors
NMDARs are the most complex of the ionotropic receptors and a primary therapeutic target for psychiatric disorders. In addition to the recognition site for glutamate, NMDARs contain neuromodulatory sites for glycine that has especially been a recent target for drug development. The glycine site, like the benzodiazepine site of the GABA receptor, affects channel open time and desensitization rate in the presence of agonist (glutamate), but does not, of itself, induce channel opening. As such, chronic treatment with glycine in rodents has been found not to induce excitotoxicity. 8, 9 Well-characterized antagonists have been developed for both the glutamate and glycine recognition sites (Figure 1 ), permitting detailed physiological investigation. In addition, the NMDAR complex contains regulatory sites that are sensitive to polyamines, Zn 2 þ , protons and redox agents such as glutathione. 10 NMDARs are blocked in a voltage sensitive manner by Mg 2 þ , which binds to a site within the NMDA ion channel. As a result, NMDARs are uniquely voltageas well as ligand (glutamate)-sensitive, which permits them to participate in multiple neurocognitive processes including long-term potentiation, 11 nonlinear amplification, 12 and coincidence detection. 13 The long time constants of NMDAR responses relative to other ionotropic receptors also permit NMDAR to participate in time-dependent processes such as attentional gating or motion detection. 14, 15 As small alterations in membrane voltage may produce large effects on NMDA activation and ultimate neuronal output, the NMDA synapse is a site at which convergent neuromodulatory inputs may produce large-scale changes in functional neuronal connectivity.
NMDA subunits NMDA receptors are composed of multiple subunits including at least one NR1 subunit and one or more modulatory subunits, labeled NR2A-NR2D. NR1 subunits are synthesized to excess in neurons, but are retained in the endoplasmic reticulum until they assemble with NR2 subunits. NR2D subunits are expressed primarily during development and normally decline to low levels in adult brain. In adults, NR2A and NR2B predominate in the forebrain, and NR2C in the cerebellum. NR2B receptors show prolonged channel open times and increased permeability relative to NR2A, facilitating LTP and developmental plasticity. With synaptic experience, the level of NR2B-containing receptors declines and levels of NR2A-containing receptors increases, discouraging further LTP. 16, 17 In order to participate in synaptic transmission, NMDAR must dock to the postsynaptic density via protein-protein interactions. The primary docking protein for NMDAR is PSD95, which is part of a larger postsynaptic density complex that regulates NMDA clustering. 18, 19 However, NMDAR may also remain unbound in the membrane at extrasynaptic sites, where they are activated only by pathological 'spillover' from the synaptic cleft. 20 Given the migration of receptors between synaptic and extrasynaptic pool, 21 alterations in NMDAR function may occur in the absence of absolute changes in NMDAR density.
Modulatory sites
Because of the multiple modulatory sites, NMDAR constitute a target-rich environment for drug research. Extensive libraries of channel site (PCP receptor) ligands have been developed, of which dizocilpine (MK-801) is most potent and selective and serves as the benchmark. A key identifying feature of the channel site is its characteristic rank order of potency, with MK-801 showing approximately 10-fold greater potency than PCP, which in turn shows approximately 10-fold greater potency than ketamine.
Glycine 22 and D-serine 23, 24 are endogenous ligands for the glycine site of the NMDAR complex. DCycloserine, an antituberculosis drug, fortuitously crossreacts with the glycine site. However, it functions as only a partial agonist, producing only 40-60% of the response seen with either glycine or D-serine. 25 Attempts to modify glycine or D-serine to produce synthetic glycine-site agonists have, so far, been unsuccessful. Thus, aside from the use of glycine or D-serine, indirect approaches must be taken to activate NMDAR via the glycine site.
Administration of exogenous glycine and/or D-serine potentiates NMDAR-mediated neurotransmission in vivo, suggesting that glycine sites are not saturated under physiological conditions. Nevertheless, glycine sensitivity varies according to NR2 subunit, with NR2A-containing NMDAR showing less sensitivity to glycine than those containing NR2B subunits. 26 Because of differential saturation under basal conditions, exogenously administered glycine or D-serine may affect NR2A-containing receptors to a greater extent than those containing NR2B subunits.
Glycine/D-serine modulatory processes Glycine and D-serine bind to the NMDAR-associated glycine binding site with affinity of approximately 100 nM, yet are present extracellularly at concentrations in the micromolar range 27 Thus, transport processes must be present that regulate intrasynaptic amino-acid levels relative to the larger extracellular pool, and 'protect' the glycine-binding site from overall brain glycine and D-serine levels.
Glycine is transported in the brain by several transporters, including Type I (GLYT1) and Type II (GLYT2) glycine transporters, and System A-family SNAT transporters. 5, 28, 29 GLYT1 and SNAT transporters, both of which are sensitive to inhibition by sarcosine (N-methyl glycine) predominate in the forebrain, whereas GLYT2 transporters are co-localized with strychnine-sensitive inhibitory glycine receptors in the hindbrain. 30 As GLYT1 transporters are coupled to only two Na þ ions, as opposed to GLYT2 transporters, which are coupled to three, they maintain relatively, shallow intracellelular to extracellular gradients. As a result, GLYT1 transporters most likely maintain synaptic glycine concentrations in the high nanomolar range. Further, GLYT1 transporters may function in either the forward or reverse direction depending upon astrocytic membrane potential, and may therefore dynamically regulate extracellular glycine levels. 31 System A transporters are expressed in both neurons and glia, and transport a range of small neutral amino acids (eg, glutamine, proline, serine) along with glycine. The role of System A transporters in glycine homeostasis is still under evaluation. SNAT2-type System A transporters, for example, mediate amino-acid efflux from the CNS across the blood-brain barrier. 32 Blockade of these transporters, therefore, would be expected to increase CNS levels of glycine along with other small neutral amino acids.
D-Serine is synthesized in the brain from glycine via serine racemase, [33] [34] [35] and degraded by actions of Damino acid oxidase (DAAO), which is primarily expressed in the cerebellum with lower expression in the forebrain. DAAO is modulated by the recently described protein G72. 36 Mechanisms underlying regulation of synaptic D-serine levels in the brain are poorly understood. Traditional transport systems show limited affinity for D-serine, although selective high-affinity D-serine transporters have recently been described. 37, 38 As with glycine transporters, these may represent selective targets for the modulation of brain D-serine levels.
AMPA/kainate receptors AMPA and kainate receptors mediate the majority of fast glutamatergic in the brain. AMPA receptors are composed of combinations of GluR1-4 subunits, and work heavily in concert with NMDA receptors. Mature AMPA receptors containing the GluR2 subunit are Ca 2 þ impermeant, 39 and thus do not directly trigger LTP. Nevertheless, AMPA receptors provide the primary depolarization necessary to unblock NMDA receptors and to permit calcium entry into the cell. Synergistically, Ca 2 þ entry through unblocked NMDA receptors triggers AMPA insertion into the postsynaptic density and synaptic strengthening. AMPA receptors, however, are continuously recycled, leading to gradual synaptic weakening. If AMPA density falls below a critical threshold, levels of depolarization are insufficient to unblock NMDA channels, preventing subsequent AMPA activation. Such synapses, despite containing histologically identifiable NMDAR, are functionally silent, and cannot be recovered by electrical stimulation alone. 40 Selective, high-potency AMPA antagonists have been developed, and may be effective in conditions such as stroke or epilepsy, which are characterized by hyperglutamatergia. 41 As AMPA receptors densensitize rapidly following stimulation, direct AMPA agonists are unlikely to be therapeutically useful. However, compounds have been developed that potentiate AMPA transmission without binding directly to the agonist binding site. 42 Termed AMPAkines, these drugs stimulate memory-dependent processing in animals, 14 and are currently under development for treatment of cognitive dysfunction in various neuropsychiatric disorders.
Metabotropic receptor
Metabotropic receptors, which serve to regulate glutamatergic neurotransmission both pre-and postsynaptically, may serve as an alternative molecular target for treatment of schizophrenia. Metabotropic receptors are divided into three groups based upon second messenger coupling and ligand sensitivity. Group I receptors are positively linked to phospholipase C, whereas both group II and III receptors are negatively linked to adenyl cyclase. 43 As a result, group I receptors function predominantly to potentiate both presynaptic glutamate release and postsynaptic NMDA neurotransmission, 44 with mGLUR5 receptors showing significant colocalization with NMDA receptors in rodents. 45 In contrast, group II and III receptors, in general, serve to limit glutamate release, particularly during conditions of glutamate spillover from the synaptic cleft. Thus, group I agonists or positive modulators would be expected to stimulate NMDAR-mediated neurotransmission, and group I antagonists to inhibit it. In contrast, group II/III agonists or positive modulators would be expected to inhibit presynaptic glutamate release. As extrasynaptic levels of glutamate are low under physiological conditions, group II/III antagonists would have minimal effects.
PCP/NMDA models of schizophrenia
Schizophrenia is currently the best established of the potential therapeutic targets for glutamate. Symptoms of schizophrenia are divided into three main clusters: positive, negative and cognitive. Negative and cognitive symptoms, in particular, respond poorly to current treatments approaches and are primary predictors of poor functional and therapeutic outcome in schizophrenia.
Psychotomimetic effects of NMDAR antagonists
The strongest line of evidence linking schizophrenia to EAA dysfunction is the finding that several psychotomimetic agents, known collectively as 'dissociative anesthetics,' induce their unique behavioral effects by blocking the NMDARassociated ionophore. 46 This finding has led, over recent years, to multiple theoretical formulations focusing on either NMDAR [47] [48] [49] or glutamergic 50, 51 dysfunction in the etiology of schizophrenia. The most widely recognized NMDAR antagonists, phencyclidine (PCP) and ketamine, have been extensively characterized in both animal models and challenge studies with normal volunteers. Several other PCP-like agents, however, have been developed over the past several decades either as 'designer drugs' (eg, TCP) or by the mainstream pharmaceutical industry (eg, dizocilpine, MK-801). The potency with which these agents bind to the NMDA-associated PCP receptor and block NMDA channels correlates closely with their ability to induce behavioral change in rodents, cognitive disruption in monkeys and psychotomimetic effects in humans. Although NMDA ligands such as PCP and ketamine may crossreact at high dose with multiple receptors (eg, D2 and 5-HT2 receptors 52 ), the rank order of these interactions corresponds poorly to the rank order for producing psychotomimetic effects, limiting the usefulness of such observations.
Cognitive and neurochemical effects of NMDA blockade
The ability of NMDAR antagonists, including both PCP and ketamine, to induce symptoms closely resembling those of schizophrenia was first documented over four decades ago. [53] [54] [55] [56] More recent studies have confirmed and extended these findings with more modern neurocognitive measures. For example, learning and memory are among the most selectively affected processes in schizophrenia, 57, 58 consistent with the critical role played by NMDAR in hippocampal LTP. 59 Similarly, PCP 60 and ketamine 61 induce a pattern of thought disorder and sensory dysfunction 62 that is statistically indistinguishable from that of schizophrenia.
Individuals with schizophrenia show greater sensitivity than normal individuals to psychotomimetic effects of both PCP 63 and ketamine, [64] [65] [66] suggesting that these compounds affect a system that is already vulnerable in schizophrenia. Even among nonschizophrenic individuals, reduced NMDAR activity, as reflected in measures such as decreased amplitude of mismatch negativity (MMN), predicts sensitivity to psychosis during ketamine challenge. 67 
Animal models
In rodents, NMDAR antagonists induce a range of acute effects, including locomotor hyperactivity, prepulse inhibition (PPI) deficits, prolongation of latent inhibition (LI), and disruption of working memory, many of which are highly reminiscent of symptom of schizophrenia. In primates, NMDAR antagonists also produce working memory 68, 69 and PPI [70] [71] [72] deficits, supporting the relevance of glutamate receptors as therapeutic targets in schizophrenia.
Despite the similarity of effect especially between animal find, care must be taken in use of these models for predicting therapeutic response in schizophrenia. Schizophrenia is a chronic disorder that develops gradually over time, with negative symptoms and cognitive dysfunction developing early and positive symptoms emerging gradually as the prodrome progresses. Thus, acute treatment models at most can be viewed as reproducing the early symptoms of schizophrenia. In humans, acute treatment with ketamine induces high levels of anxiety that are not typically seen in established schizophrenia, but fails to reproduce the hallucinatory behavior that emerges over time during the schizophrenia prodrome 73, 74 As an alternative to acute treatment models, neurodevelopmental and chronic treatment models may provide a more appropriate vehicle for drug development. Prolonged NMDAR blockade can be induced by repeated or continuous administration of NMDAR antagonists in rodents 75, 76 or primates. 77, 78 As compared with acute treatment in humans, chronic treatment in monkeys leads to appearance of hallucinatory-like behavior, 77 suggesting that dysregulation of relevant brain systems may emerge gradually over time.
Over recent years, more ecological models of schizophrenia have been reproduced by manipulation of NMDAR expression. Initial studies were performed with NR1-knockdown mice, which showed hyperactivity and social withdrawal. 79 Similar effects have been observed more recently with knockouts affecting the mouse NRe1 subunit (equivalent to rat NR2A), 80 and mutations affecting only the glycine/D-serine binding site. 81 Both mutants show persistent hyperactivity and stereotypic behaviors that are resistant to reversal with either antipsychotics or benzodiazepines, indicating that dysfunction of the glycine-site itself is sufficient to cause schizophrenia-like behavioral abnormalities. In contrast to knockdown mice, NR1 overexpressing mice show increased learning ability, 82 as do mice with partial GLYT1 receptor knockouts, 83 emphasizing the potential importance of NMDAR dysfunction to cognitive impairments in schizophrenia.
A final approach has been the use of persistent NMDAR antagonist treatment, followed by withdrawal. Studies with such models have shown persistent alterations in cognitive performance and dopamine turnover in frontal lobe. 84, 85 A caution regarding such models, however, is that psychotomimetic effects of PCP or ketamine rarely persist for more than 1-2 weeks following discontinuation of abuse, 63 even though repeated abuse may lead to persistent neurocognitive deficits. 86, 87 High doses of NMDAR antagonists, including PCP, ketamine and MK-801, lead to well-described neurotoxic effects, particularly in frontal and cingulate brain regions. 88 Thus, use of NMDAR antagonist treatment/withdrawal models may selectively model drug-induced neurodegeneration, without specifically modeling schizophrenia.
Alternative glutamatergic models

Glutamatergic
hyperactivity Following acute treatment, NMDAR antagonists stimulate prefrontal glutamate release, 89, 90 which may independently induce schizophrenia-like impairment in cognitive performance. 89 Support for a role of glutamatergic excess comes from animal studies in which ketamine-induced glutamate release and deficits in working memory performance were reduced by treatment with a metabotropic group II agonist. 91 Similarly, the antiepileptic lamotrigine reverses psychosis and cognitive dysfunction when coadministered with ketamine. 92 Prefrontal glutamate levels are also increased by chronic stress 93 and ketamine-induced behavioral alterations are blocked by AMPA/kainate antagonists as well as lamotrigine 89 leaving unresolved the specificity of this finding to schizophrenia.
Excitotoxicity/apoptosis Another alternative glutamate theory of schizophrenia is based upon the observation that NMDAR antagonists, including PCP, ketamine and MK-801 induce neurodegeneration of pyramidal neurons following acute or chronic administration. 47, 94 In this model, often termed the NRH model, it is proposed that symptoms of schizophrenia do not reflect acute NMDA blockade, but rather NMDA-induced apoptotic changes in susceptible brain regions, particularly frontocingulate areas. 47 Many treatments are known to prevent NMDA-antagonist induced neurotoxicity, including clonidine, guanabenz, benzodiazepines, and LSD. 47, 95 Few of these treatments, however, reverse the acute psychotomimetic effects of NMDAR antagonists or ameliorate persistent symptoms of schizophrenia. It is, therefore, unlikely that ongoing NMDAR-induced apoptosis contributes directly to psychotic symptoms, although persistent NMDAR hypoactivity may contribute to the gradual cognitive decline seen in some individuals with schizophrenia.
Therapeutic targets based on glutamate models of schizophrenia NMDAR glycine-site agonists To date, the strongest clinical data validating glutamatergic approaches for schizophrenia come from studies with NMDAR glycine-site agonists, which function as positive allosteric modulators of the NMDAR complex. Studies have been conducted with three separate agents: glycine and D-serine, which function as full agonists, and D-cycloserine, which functions as a partial agonist. Glycine has been found to be effective at a dose of 30-60 g/day (0.4-0.8 g/kg/ day); D-serine, at a dose of 2.1 g/day (0.03 g/kg/day) and D-cycloserine at a dose of 50 mg/day. With both glycine and D-serine, effectiveness of higher doses has not been explored so that maximal benefit obtainable from glycine-site stimulation is unknown. With Dcycloserine, doses in excess of 100 mg cause symptom exacerbation due to emergent NMDAR antagonist effects, producing a narrow therapeutic window. 96 Results of clinical trials conducted with NMDAR agonists have been consistent across studies (Table 1 ). All studies have demonstrated large effect-size (0.9-2.1 SD units) improvement in negative and cognitive symptoms when these agents are added to typical antipsychotics, or newer atypicals. Percentage improvement in negative symptoms range from 16 to 39% (weighted mean 30%) for trials in the range of 6-12 weeks. Whether greater reduction occurs during longer-term treatment, or whether tolerance develops, is currently unknown. The level of cognitive and positive symptom improvement, across studies, is roughly 15%. In some, but not all, studies degree of negative symptoms improvement correlated significantly with baseline glycine levels, suggesting that patients with lowest pretreatment levels respond best to NMDAR agonist treatment. In contrast to effects in combinations with typical or newer atypical antipsychotics, glycine site agonists may be ineffective when combined with clozapine. In double-blind, placebo-controlled studies in which glycine 97 or D-serine 98 have been added to clozapine, no significant beneficial response has been observed, while D-cycloserine is reported to lead to worsening of symptoms when used in combination with clozapine. 99 D-Cycloserine functions as a glycine site agonist in the presence of high glycine concentrations, and as an antagonist in the presence of high concentrations. 25 A parsimonious explanation for the D-cycloserine induced worsening of symptoms, therefore, is that clozapine may already increase synaptic glycine levels through as yet unknown mechanisms. Recently, clozapine has recently been shown to block glycine and glutamine transport mediated by SNAT2-like synaptosomal transporters, providing a potential mechanism for both the differential therapeutic effects of clozapine and the differential effects of NMDAR modulators in the presence of clozapine vs other antipsychotics. 29 This finding may also account for the reported ability of clozapine to increase serum glutamate levels, 100 and downregulate central glutamate transport.
101,102
Glycine transport inhibitors Both glycine and D-serine appear to be effective when used in treatment resistant schizophrenia. However, both must be given at gram-level doses in order to significantly elevate CNS levels. An alternative approach to increasing CNS levels is use of glycine transport inhibitors (GTIs), which raise synaptic glycine levels by preventing its removal from the synaptic cleft. Use of GTIs to augment NMDA functioning is analogous to use of selective serotonin reuptake inhibitors (SSRIs) to raise synaptic serotonin levels in depression.
Initial studies were performed using the relatively nonselective glycine transport antagonist, glycyldodecylamide (GDA). This drug was shown to inhibit glycine transport in cortical 103 or hippocampal 104 synaptosomes, and inhibit amphetamine-induced dopamine release 105 and PCP-induced hyperactivity in rodents. [106] [107] [108] More recent studies have been performed with selective, high-affinity GTIs such as N[3-(4 0 -fluorophenyl)-3-(4 0 -phenylphenoxy)propyl]-sarcosine (NFPS) 109 or Org 24598. 110 As with GDA, high affinity GTIs have been found to reverse PCP-induced hyperactivity 111 and dopaminergic hyperreactivity 112 in rodents, and to potentiate hippocampal LTP 113 and NMDAR-dependent responses in prefrontal cortical neurons. 114 GTIs also reverse PPI abnormalities in DBA/2J mice 113 and rats with neonatal hippocampal lesions, 115 supporting a potential role of GTIs in treatment of schizophrenia.
To date, only a single clinical trial using GTIs in schizophrenia has been conducted. In that study, sarcosine (N-methyl glycine) induced a highly significant, approximately 15% reduction in negative symptoms, along with significant reduction in positive and cognitive symptoms and total PANSS score, 116 strongly supporting the potential therapeutic utility of GTIs in schizophrenia.
Other ionotropic targets
As AMPAR function in concert with NMDAR, they have been proposed as alternative therapeutic targets in schizophrenia. In animal studies, AMPAkines act synergistically with antipsychotics to reverse amphetamine-induced hyperactivity. 117 To date, a single clinical study has been performed with the AMPAkine CX-516 added to clozapine. In this study, significant improvements in memory and attention were observed despite lack of symptomatic improvement. 118 CX-516 has also been studied as monotherapy, with no clear beneficial effects. 119 Although downregulation of AMPA receptors is less with AMPAkines than with direct agonists, there is some concern that downregulation may nonetheless occur and may limit long-term treatment strategies. 120 Lamotrigine, an antiepileptic that reduces presynaptic glutamate release, has also been proposed as a potential adjunctive medication in schizophrenia. 121, 122 In humans, lamotrigine prevented acute psychotomimetic effects of ketamine, with greater effects on positive than negative symptoms. 121 Improvements in positive and general symptoms have been reported as well in small-scale studies of lamotrigine in clozapine-treated patients with persistent clinical symptoms. 123, 124 If confirmed, these results would suggest a greater potential role of glutamatergic hyperactivity in persistent positive symptoms of schizophrenia, and of NMDAR underactivity in persistent negative symptoms.
Metabotropic receptors
Metabotropic modulators are currently in an early stage of development for treatment of schizophrenia. Studies attempting to validate metabotropic receptors as therapeutic targets in schizophrenia have been based on two alternative conceptualizations of the disorder. Group I receptors potentiate presynaptic glutamate release and NMDAR-mediated neurotransmission. Therapeutic effectiveness of group I agonists is therefore predicted based upon models which postulate low NMDAR receptor activity and/or glutamate levels as being pathophysiological in schizophrenia. In contrast, Group II/III agonists inhibit glutamate release. Use of these agents follows models, which postulate that glutamatergic hyperactivity may be pathophysiological.
Group I receptors Group I includes both mGLUR1 and mGLUR5 receptors, both of which stimulate NMDAR via differential second messenger cascades. 125, 126 Preclinical studies have evaluated the ability of Group I antagonists to induce schizophrenialike behavioral effects, and Group I agonists to reverse effects of amphetamine, PCP and other psychotomimetics. The most widely used mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), does not affect locomotor activity or PPI by itself but potentiates PCP-induced increases in locomotor activity and disruption of PPI. 127, 128 Similar effects have been observed with the more recently develop compound 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP). 129, 130 Finally, mGluR1 131 and mGluR5 128 knockout mice show disruptions of PPI, which respond poorly to known treatments for schizophrenia, 132 supporting a potential role of Group I receptors as therapeutic targets in schizophrenia. Group I antagonists also produce anxiolytic-like effects in several animal models of anxiety, suggesting that they may be independent targets for the treatment of anxiety disorders. 133 Studies with Group I agonists have also been supportive of potential therapeutic effectiveness, but are more limited. For example, the mGluR5 agonist 2-chloro-5-hydroxyphenylglycine (CHPG) has been found to reverse PPI-disruptive effects of amphetamine in rodents. 128 Similarly, both nonselective and Group I selective agonists inhibit PCP-induced dopamine release in rodent prefrontal cortex. 134 An issue in the use of direct agonists is rapid receptor desensitization, preventing chronic use. An alternative approach is the use of positive allosteric modulators, which, do not bind directly to the agonist-binding site. Positive modulators, in general, have proven to be lipophilic and centrally acting, making them attractive as potential pharmacological agents. 135 Despite some encouraging results with Group I agonists in animal models, clinical data remain lacking. Further, group I receptors have a markedly different cellular distribution in primates than rodents. 136, 137 Thus, primate studies and eventual clinical trials will be needed to validate this target for treatment of neuropsychiatric disorders.
Group II metabotropic agonists Group II and III metabotropic receptors are negatively linked to glutamate release, and may limit endogenous release under conditions of glutamate excess. Use of Group II/III agonists in schizophrenia is therefore based upon the hypothesis that increased glutamate levels may be pathophysiological. Several high-affinity agonists have been developed over recent years, including (À)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY-379268) and the related compound LY-354740, permitting characterization of effects of Group II agonists in both preclinical and clinical studies. 138 An initial study with LY-379268 demonstrated its ability to block PCP-induced increases in prefrontal glutamate, along with PCP-induced impairments in working memory, suggesting a role of glutamatergic hyperactivity in at least some forms of prefrontal dysfunction. 90, 91 Similarly, LY3279268 has been shown by a variety of groups to inhibit PCPinduced hyperactivity during both acute 139, 140 and repeated 141 administration, and reverse PCP-induced behaviors in monoamine depleted mice. 142 Finally, these drugs reverse ketamine-induced stimulation of ventral hippocampal norepinephrine release, which may also be linked to prefrontal hyperglutamatergia. 143 In contrast to its effects on glutamate, group II agonists do not inhibit, 90 and may enhance, 134 NMDAR antagonist effects on PFC DA release, suggesting a dissociation in the regulation of prefrontal glutamate and dopamine systems. Group II agonists also do not reverse PCP-induced behavioral sensitization, 141 PCP-or apomorphine-induced disruption of PPI, 144 or MK-801-induced disruption in delayed alternation. 144 Based upon the effect of group II agonists on prefrontal glutamatergic hyperactivity, it has been proposed that these agents may be therapeutically beneficial in treating persistent cognitive deficits in schizophrenia. 91, 138 At present, however, the degree to which psychotomimetic effects of PCP are related to alterations in glutamatergic vs dopaminergic neurotransmission is not known. Clinical trials of mGluR2 agonists may thus help clarify pathophysiological mechanisms in schizophrenia. To date, no significant beneficial effects of LY-354740 or other group II agonists have been reported.
Group II receptors, like Group I receptors, may desensitize during chronic treatment. As with Group I receptors, therefore, positive allosteric modulators may ultimately prove more useful than direct agonists. 90, 135, 145 Group III metabotropic receptors are less studied than groups I or II. Nevertheless, group III agonists, like group II agonists, may induce antianxiety and antidepressant effects, and may also represent an appropriate therapeutic target. 146 
Nonpsychotic disorders
Although glutamate receptors have been studied most intensively in relationship to psychotic disorders, both ionotropic and metabotropic receptors may also represent appropriate targets for other neuropsychiatric disorders. Stimulation of glutamatergic systems may be beneficial in disorders associated with primary memory disturbances, whereas inhibition may be beneficial in disorders associated with neurodegeneration. Effects of glutamatergic agents have been studies most intensively with regard to Alzheimers disease (AD), anxiety, depression and PTSD.
Alzheimer disease
Alzheimer disease (AD), like schizophrenia, shows widespread neuronal changes, indicating involvement of cortical glutamatergic systems. In Alzheimers disease, NMDAR antagonists have been used to attempt to slow excitotoxic neurodegeneration. In particular, memantine, a weak NMDAR channel blocker, has shown safety and efficacy in slowing decline in moderate to advanced AD. 147 The tolerability of memantine relative to other channel blockers (eg, PCP, MK-801) appears to be due to its low affinity, fast unblocking kinetics and limited liability for trapping within closed channels. 148 In contrast to stroke or hypoxia where excitotoxicity is due to excessive phasic glutamate release, excitotoxicity in AD has been proposed to result from tonic glutamatergic overactivation, possibly due to loss of normal voltage-dependent Mg 2 þ blockade of NMDAR. Memantine, which functions analogously to Mg 2 þ in producing voltage-dependent NMDAR blockade, may thus take over the physiological role of Mg 2 þ .
149
Glutamatergic hyperactivity may be of particular relevance to AD due to a specific role of a beta-amyloid in the regulation of astrocytic glutamate clearance mechanisms. 150, 151 To the extent that this process underlies neurodegeneration in other disorders, memantine may prove effective as well.
Based upon effectiveness of memantine, other glutamate-reducing treatments have also been proposed for treatment of AD. These include Group I metabotropic antagonists, which would be predicted to reduce NMDAR activation, 152 and group II/III agonists, which are reported to prevent neurodegeneration in a variety of clinical models. 138 To date, however, clinical data are lacking.
As deficits in learning and memory are central to AD, NMDAR and AMPAR agonists would be predicted to have immediate symptomatic benefit, although potentially at the expense of increased neurodegeneration. The most widely studied compound to date has been D-cycloserine. A large-scale double-blind, placebo controlled trial of 5, 15 and 50 mg/day D-cycloserine for treatment of AD failed to show overall significant benefit, 153 although some effect on implicit memory was observed. 154 Since then, conflicting results with higher doses have been reported, with one study failing to find efficacy in a dose-escalation study, 155 but another study finding efficacy of a fixed dose of 100 mg/day Dcycloserine on cognitive functioning. 156 Limited effectiveness of NMDAR glycine-site agonists may related to the reported loss of glycine binding sites in AD, 157 although studies with full glycine-site agonists appear warranted. AMPAkines are also under active investigation for treatment of AD, with SBIRfunded clinical trials scheduled for completion in the second quarter of 2003. 158 
Anxiety
At present, the primary treatments for anxietybenzodiazepines and barbiturates-function by increasing inhibitory, GABAergic neurotransmission. On the simplest level, a similar neurochemical effect could be achieved by reducing excitatory glutamatergic neurotransmission. Inhibitors of presynaptic glutamate release, AMPA receptor antagonists, or group II or III metabotropic agonists could in theory, achieve such an effect. More specific data implicating glutamate in anxiety disorders comes from findings that both stress 93 and acute treatment with NMDAR antagonists 89, 91 increase prefrontal glutamate levels in rodents. Although most studies emphasize the psychotomimetic effects of acute NMDAR treatment in humans, anxiogenic effects are equally pronounced, 73, 74 and, as opposed to psychotomimetic and cognitive effects, can be reversed by treatment with lorazepam. 159 Lamotrigine has proven effective in treatment of agitation in rapid cycling bipolar disorder, 160 but no data are yet available relating to treatment of primary anxiety disorders with either lamotrigine or AMPA antagonists. 133 In contrast, preclinical anxiolytic effects have been reported for both group I antagonists and group II metabotropic agonists. 133 Further, the group II agonist LY-354740 was recently shown to be effective in reducing fear-of-shock induced startle potentiation and subjective anxiety in normal volunteers, although it was ineffective in potentiating darkness-induced startle augmentation. 161, 162 This agent also produces anxiolytic-like effects in rodents supporting the concept that such agents may serve as novel anxiolytics. 162 To the extent that group II agonists ultimately prove more effective as anxiolytics than antipsychotics, 163 it would suggest that preclinical glutamatergic hyperactivity may be more relevant to anxiety disorders than psychosis.
Depression
As opposed to schizophrenia where NMDAR agonists may prove effective, some data suggest a therapeutic role for NMDAR antagonists in depression. The original observations date back to the early 1960s, with the observation that tuberculosis patients treated with D-cycloserine at NMDAR antagonist doses showed clinical improvement. 164 At the time, interactions of D-cycloserine with NMDAR had not yet been described, and the observation with D-cycloserine was ignored in favor of monoamine oxidase inhibitors. Since then, other noncompetitive and competitive NMDAR antagonists were also shown to have antidepressant like effects in animal models, although clinical utility of these agents is limited by psychotogenic potential in humans. 165 Most recently, lamotrigine has proven effective in treatment of persistent depression in bipolar disorder, 160 and single doses of ketamine have been reported to produce antidepressant effects persisting for over 72 h following infusion in unipolar depressed patients. 166, 167 Preclinical antidepressant-like effects have also been reported for group I metabotropic antagonists, which would be expected to inhibit NMDAR-mediated neurotransmission, 168 as well as for group II 162 and group III 169 metabotropic agonists.
At present, mechanisms underlying potential antidepressant effects of glutamate antagonists remain unclear. One observation is that these agents induce downregulation of b-adrenergic receptors, an effect common to other antidepressant treatments. 165 Depression is also associated with disturbances in hippocampal LTP 170, 171 and neurogenesis, 172,173 which might be affected either by NMDAR blockade or subsequent rebound. The finding that antidepressant effects of ketamine do not begin until after clearance of ketamine from serum and cessation of its psychotomimetic effects in particular support a rebound hypothesis, and correspond to preclinical studies showing increased neurogenesis 2-7 days following acute NMDAR antagonist treatment in rodents. 174 In preclinical studies, chronic MK-801 treatment prevents both neurochemical and behavioral consequences of antidepressant treatment, 175, 176 leaving unresolved the ideal role of NMDAR antagonist treatment in the management of persistent depression.
PTSD
A final condition for which glutamate receptors might serve as therapeutic targets is PTSD. In PTSD, pathological associations are learned under conditions of extreme stress, and must subsequently be unlearned. Stress induced reductions in hippocampal plasticity and neurogenesis may also contribute to difficulties in memory unlearning NMDAR play a highly selective role in reversal learning. In animals, NMDAR antagonists produce deficits in reversal learning at doses that do not inhibit learning of primary tasks. 177, 178 Further, low dose D-cycloserine stimulates reversal learning in septally 179 and hippocampally 180 lesioned rats. In one pilot study, treatment with D-cycloserine (50 mg/day) significantly reduced PTSD symptoms and improved cognitive performance as measured by WCST. 181 However, similar behavioral effects were observed in the placebo group, necessitating larger scale studies with both partial and full NMDAR agonists. Further, preclinical studies would suggest that ideal use of these compounds would be in combination with other forms of desensitization treatment.
Summary
Whereas the role of acetylcholine in neurotransmission was discovered in the 1920s, and that of monoamines was discovered in the 1950s, glutamate was not shown definitively to serve as a neurotransmitter in the mammalian nervous system until the 1970s, and glutamate receptors were not differentiated until the early 1980s. It is not surprising therefore that therapeutic drug development for glutamatergic neurotransmitters is substantially behind that for other systems. To date, pharmaceutical company activity has been geared primarily to the creation of direct agonists and antagonists of the various ionotropic and metabotropic receptors. More nuanced treatment, however, may be possible with agents that serve as modulators, rather than direct agonists or antagonists of the various receptors. Further, as with monoamine and acetylcholine systems, synthetic and degratory enzymes, and especially neurotransmitter reuptake sites, may prove highly effective targets for psychotherapeutic development.
In the case of NMDAR, the glycine regulatory site is a target of active drug development, with glycine site agonists such as glycine, D-serine and D-cycloserine currently under development as treatments for persistent negative symptoms of schizophrenia. Highaffinity antagonists for GLYT1-type glycine transporters have also been developed and shown to be systemically active. More recently described D-serine and small neutral amino-acid (SNAT) transporters may serve as additional targets. Further, distinctive clinical effects of clozapine may result from its inhibition of SNAT2-like amino-acid transport. Memantine, a low-affinity NMDAR channel blocker, appears to slow neurodegeneration in Alzheimers disease, potentially by blocking neurotoxic effects of tonically elevated synaptic glutamate concentrations.
In the case of AMPA receptors, positive allosteric modulators (AMPAkines) have been developed and are undergoing clinical development for cognitive dysfunction in schizophrenia along with other neurocognitive disorders. Direct agonists, antagonists, and allosteric modulators have been developed for group I and group II metabotropic receptors, and are undergoing clinical development for both schizophrenia and anxiety disorders. Other diseases that may respond to glutamatergic or antiglutamatergic treatments include depression, where rebound from NMDAR blockade may trigger therapeutic neurogenesis, and PTSD, where positive NMDAR modulators may prove therapeutically effective especially in combination with behavioral therapy.
At present, many of the key compounds required for both preclinical and clinical testing in this area remain proprietary. As these compounds become more generally available, it is expected that progress in development of glutamatergic therapies will continue to accelerate.
